Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by bluemoons20on Aug 08, 2023 8:15am
80 Views
Post# 35577065

RE:RE:Any day now…

RE:RE:Any day now…Very interesting dynamic  here.

Shiseido  has done all the work and spent the money  - if the  test results  showed  nothing  , you would think  they would just  walk away.  If there is a glimmer of hope  , at this point they  are here and would have the first right to  negotiate a deal.  Unless they feel there is more work  needed  and they may get something in the arbitration and hence be able to strike a better deal??
For Replicel  ,  if  results look good  , maybe  Shiseido  low-balled them  and so they think  if they win  , they can  open the product up to the market and get better bids  from other companies after its over???

So perhaps the serious negotiations will be after  the  arbitration??

lets  hope that is the case  and the numbers are good.

The  answer could  come  out  today  , this week  or very shortly.  It is just  sad that  no one is telling us what  the timelines are.  That  is not confidential  , in my opinion.

GLTA
<< Previous
Bullboard Posts
Next >>